ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Durata Therapeutics, Inc." (DRTX) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Durata Therapeutics, Inc." (DRTX)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: UTHR, ACHN, CMRX, MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Durata Therapeutics, Inc."© quotemedia

Company Profile

Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase III clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois.

Recent News: "Durata Therapeutics, Inc."